Editas Medicine Inc (8EM)

Currency in EUR
2.85
-0.01(-0.35%)
Closed·
8EM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.852.85
52 wk Range
1.093.79
Key Statistics
Bid/Ask
2.84 / 2.87
Prev. Close
2.87
Open
2.85
Day's Range
2.85-2.85
52 wk Range
1.09-3.79
Volume
-
Average Vol. (3m)
5.07K
1-Year Change
133.2242%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
8EM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Editas Medicine Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Compare 8EM to Peers and Sector

Metrics to compare
8EM
Peers
Sector
Relationship
P/E Ratio
0.0x−2.0x−0.5x
PEG Ratio
0.00−0.090.00
Price / Book
0.0x2.1x2.6x
Price / LTM Sales
0.0x68.5x3.2x
Upside (Analyst Target)
0.0%382.1%45.7%
Fair Value Upside
Unlock3.3%4.8%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

8EM Income Statement

People Also Watch

13.030
RCAT
+3.09%
23.90
LUNR
+0.97%
10.020
ONDS
+6.59%
1.230
RXT
-0.81%
891.66
SNDK
-5.59%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.